A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
研究单位：[1]Hoffmann-La Roche[2]Affiliated Hospital of Hebei University,Baoding,China[3]Cancer Hospital Chinese Academy of Medical Sciences.,Beijing,China,100021[4]West China Hospital of Sichuan University,Chengdu City,China,610041[5]The Affiliated Cancer Hospital of Guizhou Medical University,Guiyang,China[6]Harbin Medical University Cancer Hospital,Harbin,China,150081[7]Anhui Province Cancer Hospital,Hefei City,China,230031[8]The First Affiliated Hospital Of Shandong First Medical University,Jinan City,China,250014[9]Qilu Hospital of Shandong University,Jinan,China,250012[10]Dongyang People's Hospital,Jinhua,China[11]The Third Hospital of Nanchang,Nanchang City,China,330009[12]Guangxi Cancer Hospital of Guangxi Medical University,Nanning,China,530021[13]China Medical University (CMU) First Affiliated Hospital,Shenyang City,China,110001[14]Tianjin Cancer Hospital[15]Department of Breast Oncology,Tianjin,China,300000[16]Cancer Hospital Affliated to Xinjiang Medical University,Urumqi City,China,830011[17]Union Hospital of Tongji Medical College, Dept. of Cancer Center[18]Cancer Center,Wuhan,China,430023[19]Hubei Cancer Hospital,Wuhan,China,430079[20]First Affiliated Hospital of Medical College of Xi'an Jiaotong University,Xi'an,China,710061[21]Yibin Second People's Hospital,Yibin,China[22]Zhejiang Cancer Hospital,Zhejiang,China,310022
研究目的：
This study is a post-marketing, observational, multicenter, prospective study. It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice.
